Shaily Engineering Plastics LtdNSE: SHAILY
Open the Shaily Engineering Plastics Ltd page
Follow Shaily Engineering Plastics LtdFree account. Get a note when Shaily Engineering Plastics Ltd files.
Q4 FY26 earnings call · May 25, 2026

Shaily Engineering Plastics Ltd Q4 FY26 Earnings Call: Secures Rs. 4,423 Crore Pen Injector Order, EBITDA Margin Expands 630 bps

Cofacto ResearchPublished May 25, 20265 min read
Quick summary

Shaily Engineering Plastics Ltd held its Q4 FY26 earnings call on May 19, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Record Profitability in a Transition Year

  • FY26 consolidated revenue: Rs.991 crores— up 26% YoY, with healthcare surging 139% to Rs.393 crores (40% of total vs 21% in FY25).
  • FY26 EBITDA: Rs.288 crores (29% margin)— up 61% YoY, with margins expanding 630 bps YoY; PAT at Rs.170 crores (17.2% margin), up 83% YoY.
  • Q4 FY26 revenue: Rs.237 crores— up 9% YoY, with healthcare at Rs.113 crores (+110% YoY) partially offset by consumer at Rs.102 crores (-31% YoY).
  • Q4 EBITDA: Rs.69 crores (29.3% margin)— up 27% YoY, with margins expanding 420 bps YoY; PAT at Rs.40 crores (17% margin), up 40% YoY.
  • Cash PAT for FY26: Rs.219 crores— up 62% YoY, reflecting strong cash generation alongside earnings growth.
  • ROCE of 35.8%, ROE of 26.9%— with debt-to-equity at 0.3x and fixed asset turnover at 1.7x as of March 31, 2026.
  • Consumer segment declined 9% to Rs.512 crores in FY26— driven by weakening US/Europe home furnishing demand and Q4 Middle East order cancellations due to the war.

Semaglutide Pens Drive Healthcare Transformation

  • Healthcare revenue surged 139% to Rs.393 crores in FY26— becoming 40% of consolidated revenue (up from 21% in FY25), driven by commercial semaglutide pen supplies.
  • Commercial pen injector supplies commenced in Q4 FY26— for both India and Canadian markets, with a customer receiving tentative US approval.
  • Rs.4,423 crore pen injector order from a large domestic pharma company— spread over four years; customer name withheld under NDA.
  • CRV pen volumes: 23.5 million units in FY26— below the guided 25.6–26 million due to capacity constraints; management guided ~36 million for FY27 and ~50 million for FY28.
  • Canada launches saw positive early feedback— only two complaints received (user error and printing issue); management stated ~70% of top six Canadian filers use Shaily's device.
  • No commercial agreements with innovator GLP-1 companies as of May 2026— management confirmed no signed agreements or commercial engagements with innovative GLP-1 segment players.
  • Brazil launch expected by end of May/June 2026 (Q1 FY27)— with Turkey and Mexico launches to follow; no specific timeline provided for the latter.

Semiconductor & Consumer Electronics Open New Avenues

  • Shaily is the sole Indian manufacturing partner for a Korean semiconductor customer— supplying conductive plastic trays to OSAT players in India, with commercial supplies expected from Q4 FY26-27.
  • FY27 chip tray supply target: 36 million units— corrected from an earlier mention of 40–42 million; management views this as a volume-driven consumable business.
  • Consumer electronics component supplies commenced in Q4 FY26— with shipments in India and for export; management reiterated a multi-year opportunity over 5 years.
  • Consumer electronics EBITDA margins to remain single-digit— until scale reaches ~$15–20 million, as overheads stay high initially due to technical complexity (Amit Sanghvi, MD).
  • Global competitors exist in Korea, China, and the Philippines— but management noted chip manufacturers would likely avoid daily imports over a longer horizon, supporting local production.
  • Eye applicator machines commissioned for a single customer— replacing an imported item for regulated markets; commercialization planned for FY26-27.

Pen Injector Capacity Triples; Efficiency Improving

  • Pen injector capacity to reach 80 million units— 30M existing + 25M added in March (Q4 FY26) + 25M planned by July–August (Q2 FY27).
  • New 25M semaglutide line running at ~45% OEE— at 34–35 ppm on an 80 ppm line; management targets 65–67 ppm by end of FY27 for both new lines.
  • Rejection rate reduced to 8%— down from ~30% in Q3 FY26;breakdown issues need permanent resolution.
  • Machine utilization improved to 47.6% in FY26— up from 42.2% in FY25, reflecting better capacity deployment.
  • Investment cycle for new lines extended to 18–24 months— from trigger to on-stream (previously ~12 months); future capacity additions should see lower initial rejection rates.
  • Target combined optimal capacity of 40–42 million pens for FY27— from the two new lines; management targets 35–40 million pens from new capacity by end of FY28 (March 2028).
  • Abu Dhabi greenfield capex progressing— geopolitical tensions seen as short-term with buffer factored in; benefits include lower operational costs, supply chain ease, and international talent access.

Sustainable Margins Above 28%; Consumer Drag Easing

  • Sustainable EBITDA margin of ~28%+ confirmed— management stated the current ~28%+ margin is sustainable even after Abu Dhabi capacity expansion, with expected year-on-year improvement.
  • Healthcare segment now 40% of revenue— up from 21% in FY25, shifting the mix toward higher-margin pen injector products.
  • Consumer segment declined to 52% of revenue— down from 71% in FY25, with degrowth accelerating in H2 FY26 due to US/Europe demand weakness and Q4 Middle East order cancellations.
  • UK subsidiary margins were lowest in Q3 and Q4 FY26— attributed to longer-term milestone-based projects and a shift toward next-gen drug delivery devices; management advised looking at combined UK+UAE margins.
  • Industrial segment grew 41% to Rs.87 crores in FY26— providing a small but growing diversification benefit.
  • Consumer recovery depends on global situation improving— management declined to specify when consumer demand might rebound or provide a quarterly revenue breakdown.

FY27 Priorities: Scale, Build, Deepen, Restore

  • FY27 pen injector volume guidance: ~36 million units— with capacity ramp-up risk flagged for new lines arriving in August FY27; FY28 target at ~50 million units.
  • Board approved enabling resolution to raise up to Rs.500 crores for FY26-27— for time-sensitive, capital-intensive opportunities requiring 50–100 million devices/year capacity (e.g., auto-injectors), with supplies from Q4 FY26-27.
  • FY27 priorities: scale healthcare, build Abu Dhabi facility, deepen consumer electronics & semiconductor programs, restore consumer growth— as stated by management.
  • Overall pen production target of 40–60 million units in 24–30 months— (approximately FY28–FY29), reflecting the multi-year ramp trajectory.
  • Management expressed confidence in sustainable growth years ahead— citing FY26 execution and continued operational improvement as foundation.
  • Management declined to provide quarterly revenue breakdown or specific consumer rebound timeline— maintaining a conservative disclosure stance on near-term visibility.

Ask about this

Ask Cofacto a question about this call. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This earnings call summary is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.